Retatrutide appetite suppressant treat obesity and type 2 diabetes from UK
Description
Description
How Retatrutide Works
Retatrutide is known as a triple hormone receptor agonist, meaning it activates three metabolic pathways at once:
GLP-1 receptor – reduces appetite, slows gastric emptying, improves blood sugar control
GIP receptor – enhances insulin response and energy balance
Glucagon receptor – increases energy expenditure and fat burning
This triple-action mechanism is what makes Retatrutide different from medications like semaglutide or tirzepatide (which act on one or two receptors only).
Effectiveness (Clinical Trial Data)
In mid-to-late phase clinical trials:
Average weight loss:
22%–24% of total body weight over ~48 weeks
Blood sugar control:
Significant reductions in HbA1c, even in patients with long-standing type 2 diabetes
Waist circumference & visceral fat:
Marked reduction, suggesting real metabolic improvement, not just appetite suppression
These results place Retatrutide among the most potent weight-loss drugs ever studied.
Administration
Route: Subcutaneous injection (similar to insulin pens)
Frequency: Once weekly
Dose escalation: Gradual increase to reduce side effects.
Common Side Effects
Most side effects are gastrointestinal, especially during dose escalation:
Nausea
Vomiting
Diarrhea
Constipation
Reduced appetite
Fatigue (less common)
These effects are similar to GLP-1–based drugs and usually improve over time.
